IRVINE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a developer and manufacturer of diagnostic test systems and CDMO services provider, today announced it has entered into...
IRVINE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global biomedical technology company focused on innovative diagnostic-guided therapies, today announced that an...
The Medicare Administrative Contractor (MAC) responsible for processing inFoods® IBS claims has confirmed to Biomerica’s certified laboratory partner that the test will be reviewed on an individual,...
— Represents Biomerica’s First Commercial Entry into the Canadian Market for its Precision, Diagnostic-Guided Therapy — Canada Has One of the Highest IBS Prevalence Rates in the World — an...
IRVINE, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (“Biomerica” or the “Company”) a global provider of advanced medical diagnostic and therapeutic products today...
First Commercial Order by Large Lab Chain: Biomerica has received its first commercial order for Hp Detect™, from one of the largest clinical laboratory chains operating across Europe. Strategic Account:...
UK Market Entry: MHRA registration authorizes hp+detect™ for commercial sale in Great Britain Active Commercialization: Biomerica is in active discussions with UK partners to access the diagnostic...
Key Highlights Responder Analysis: 59.4% of patients achieved ≥30% reduction in abdominal pain; 68.1% achieved ≥30% reduction in bloating—using the FDA-recognized responder endpoint consistent...
Approval Marks Biomerica’s Strategic Entry into Southeast Asia’s Rapidly Growing Healthcare Market Simple, FDA-Cleared At-Home Test Detects an Early Warning Sign of Colorectal Cancer in Minutes ...
Operating Expenses Decline 4% Year-to-Date Balance Sheet Strengthens and Working Capital Improves by 14.7% IRVINE, Calif., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA),...